Clinical Commander

All dossiers
cardio.cardiogenic-shock.anthracycline-cardiotoxicity.v1

Cardiogenic shock — anthracycline-induced cardiomyopathy with shock physiology

cardiologyacuteadultacuteinpatienttransitionoutpatient
Start encounter →Print handoutPRODUCTION

Phase E variant of cardio.cardiogenic-shock.core.v1 — narrowed to anthracycline-induced cardiomyopathy with shock physiology. Distinguished from cardio.acute-hf.chemotherapy-induced.v1 by hemodynamic profile (this engine = SBP <90, lactate ≥2, MAP <65, SCAI Stage C–E; sibling = warm with congestion). Risk factors per Lyon ESC 2022 cardio-oncology PMID 36017575 + AHA 2022 cardio-onc: cumulative dose (doxorubicin >450 mg/m² with sharp incidence rise >550; daunorubicin >550; epirubicin >900); concurrent thoracic radiation (synergistic — left chest XRT in left-sided breast cancer or Hodgkin lymphoma); concurrent / sequential trastuzumab (additive cardiotoxicity per Slamon NEJM 2001 PMID 11248153); older age (>65), pre-existing cardiac disease, hypertension, diabetes, obesity. Treatment ACUTE: standard CS support (NE first-line per SOAP-II PMID 20200382); GDMT 4-pillar with carvedilol + ARNI/ACEi + MRA + SGLT2i specifically anchored on Cardinale 2015 PMID 25956652 (enalapril cardioprotection — partial recovery in 64% within 6 mo) + PRADA trial (Heck JAMA Cardiol 2021 candesartan/metoprolol prevention) + HOMER trial (empagliflozin emerging in anthracycline-CMP); MCS bridge to recovery is reasonable given partial-recovery rate 40–60%. Cancer-treatment decisions: DISCONTINUE further anthracycline; oncology coordination on switch to non-cardiotoxic regimen (taxane, capecitabine, immunotherapy per cancer type); HOLD trastuzumab if concurrent. Dexrazoxane (Swain JCO 1997 PMID 9263800) FDA-approved as cardioprotectant for metastatic breast cancer patients receiving cumulative doxorubicin ≥300 mg/m² who would benefit from continued anthracycline therapy. Transplant eligibility despite cancer history: historical ISHLT 2016 disease-free interval ≥5 yr for solid tumors / ≥1 yr for hematologic being relaxed; case-by-case per modern criteria with cardio-onc + transplant + oncology MDT input. Recovery + cancer continuation balance is the key chronic-phase decision. Surveillance: routine baseline + serial echo with LVEF + GLS during therapy (every 3 cycles or per protocol per ESC 2022); GLS ≥15% relative reduction from baseline triggers cardioprotection per Thavendiranathan SUCCOUR JAMA Cardiol 2021; long-term cardio-onc surveillance annual echo + GLS + CV risk assessment. Status INTEGRATED until terminology + RxNav-validated drug codes are reconciled. Authored 2026-05-15 by shard-06-cardio-acute as Phase E wave 13 cancer-related variant.

Entry points (5)

  • history
    Cumulative doxorubicin >450 mg/m² (or equivalent — daunorubicin >550, epirubicin >900) + acute LV dysfunction + shock physiology → anthracycline-CMP with CS
    cumulative_doxorubicin_above_threshold_with_acute_hf_and_shock
  • history
    Concurrent / sequential anthracycline + trastuzumab + acute LV dysfunction with hypoperfusion → additive cardiotoxicity per Slamon 2001 PMID 11248153
    concurrent_anthracycline_trastuzumab_with_acute_hf_and_shock
  • imaging
    Severe global LV dysfunction (EF <30) with diffuse pattern (not single coronary territory) on echo + GLS markedly reduced + recent anthracycline exposure
    echo_severe_lv_dysfunction_with_diffuse_pattern_in_anthracycline_treated_patient
  • lab_abnormality
    Persistent high-sensitivity troponin elevation during anthracycline therapy + new LV dysfunction (Cardinale Circulation 2004 PMID 15067104 — predicts later cardiotoxicity)
    troponin_elevated_during_anthracycline_therapy_with_lv_dysfunction
  • history
    History of left chest radiation (breast cancer or Hodgkin lymphoma) + anthracycline + acute HF → synergistic cardiotoxicity per Lyon ESC 2022 PMID 36017575
    thoracic_radiation_plus_anthracycline_with_acute_hf

Required inputs (15)

  • agerequired
    demographic • used at CONTEXT
    Older patients (>65) higher cardiotoxicity risk; informs prognosis + transplant candidacy
  • cumulative_anthracycline_doserequired
    history • used at CONTEXT
    Doxorubicin >450 mg/m² or equivalent — primary risk factor; informs continuation decision and risk-stratifies recovery probability
  • concurrent_trastuzumab_or_thoracic_radiationrequired
    history • used at CONTEXT
    Synergistic cardiotoxicity drivers; modifies treatment + prognosis
  • cancer_status_remission_or_activerequired
    history • used at CONTEXT
    Disease-free status determines transplant eligibility (typically ≥5 yr for solid tumors per ISHLT 2016 historical; case-by-case modern); active malignancy modifies aggressiveness of CV care
  • sbprequired
    vital • used at RED_FLAGS
    SCAI 2022 staging baseline; gates vasopressor escalation
  • hrrequired
    vital • used at CONTEXT
    Tachycardia common in CS; bradyarrhythmia in advanced HF; AV block possible in cumulative anthracycline
  • troponinrequired
    lab • used at INITIAL_WORKUP
    High-sensitivity troponin — early subclinical injury marker per Cardinale Circulation 2004 PMID 15067104
  • bnp_ntprobnprequired
    lab • used at INITIAL_WORKUP
    Acute HF marker; trend tracks recovery during cardioprotective therapy
  • lactaterequired
    lab • used at RISK_STRATIFICATION
    SCAI 2022 staging + CardShock prognostication (Harjola EHJ 2015 PMID 26333869)
  • creatininerequired
    lab • used at CONTEXT
    End-organ damage marker; eGFR for ARNI / SGLT2i / ACEi / contrast / gadolinium dosing
  • cbc_with_diffrequired
    lab • used at INITIAL_WORKUP
    Cancer treatment cytopenia surveillance; baseline for ongoing cancer care decisions
  • echorequired
    imaging • used at INITIAL_WORKUP
    LVEF + GLS — primary diagnostic + surveillance modality per ESC 2022 + Plana JASE 2014; diffuse global pattern (not single coronary territory)
  • ecgrequired
    imaging • used at INITIAL_WORKUP
    Sinus tachycardia, low voltage, non-specific ST/T changes; conduction abnormalities possible in cumulative dose
  • cmr
    imaging • used at BRANCHING_WORKUP
    LVEF + diffuse mid-wall LGE pattern; T1 mapping for diffuse fibrosis; rules out alternative cardiomyopathies; prognostic for recovery
  • cor_angiorequired
    imaging • used at BRANCHING_WORKUP
    Mandatory rule-out of obstructive CAD when shock + LV dysfunction (anthracycline-CMP can mimic AMI); thoracic-radiation patients have premature CAD risk

12-phase flow (11)

  1. 1FRAME
    Confirm anthracycline-CMP as the shock etiology — cumulative dose history + diffuse global LV dysfunction + no obstructive CAD pattern; assess concurrent cardiotoxic factors (trastuzumab, thoracic radiation); cancer status (remission vs active) shapes long-term decisions
    inputs: cumulative_anthracycline_dose, concurrent_trastuzumab_or_thoracic_radiation, cancer_status_remission_or_active, echo
    advance: Anthracycline-CMP with shock confirmed and cumulative-dose risk-tier assigned
  2. 2ENTRY
    CS team activation; emergent cath to exclude obstructive CAD (mandatory MI mimic rule-out + premature CAD screen if thoracic radiation history); STAT echo for biventricular function + GLS; mobilize cardio-oncology + oncology + advanced HF MDT
    inputs: sbp, lactate
    advance: CS team + cardio-onc + oncology activated, obstructive CAD excluded
  3. 3CONTEXT
    Cumulative anthracycline dose; concurrent trastuzumab / thoracic radiation; cancer status (remission vs active) + disease-free interval; prior cardiac history; baseline LVEF + GLS; current oncology regimen; comorbidities (HTN, DM, CKD, obesity)
    inputs: hr, creatinine
    advance: Cardio-oncology context complete; cumulative dose risk-tier assigned
  4. 4RED_FLAGS
    Refractory CS (escalate to MCS — anthracycline-CMP often shows partial recovery so MCS bridge is reasonable); ventricular arrhythmia (high-risk in dilated anthracycline myopathy); cardiac arrest (E-CPR consideration with cardio-onc input)
    inputs: sbp, hr
    actions: cardiogenic_shock
    advance: Arrhythmia and refractory shock screened, MCS pathway evaluated with MDT
  5. 5INITIAL_WORKUP
    ECG, echo (LVEF, GLS, biventricular function, diffuse pattern), high-sensitivity troponin, NT-proBNP, BMP, lactate, CBC w/ diff, LFTs (cancer-treatment hepatotoxicity), CXR; SCAI 2022 staging; baseline GLS for recovery tracking
    inputs: ecg, echo, troponin, bnp_ntprobnp, lactate, cbc_with_diff
    actions: cardiogenic_shock, panel.cardiac, panel.renal, panel.cbc
    advance: Workup complete and SCAI stage assigned with cumulative-dose context
  6. 6BRANCHING_WORKUP
    Cardiac MRI (LVEF + diffuse mid-wall LGE + T1 mapping for diffuse fibrosis); coronary angiography (mandatory MI mimic rule-out + premature CAD screen if thoracic radiation history); CMR for prognostic recovery assessment; oncology coordination for cancer disease-status update
    inputs: cor_angio
    advance: Diffuse anthracycline-CMP pattern confirmed and obstructive CAD excluded
  7. 7RISK_STRATIFICATION
    SCAI 2022 staging; CardShock prognostication; cumulative-dose tier (high if doxorubicin >450, very high >550); concurrent risk factors (trastuzumab, thoracic radiation, age >65); cancer disease-status (active vs remission); recovery probability estimate per Cardinale 2015 (PMID 25956652) — partial recovery 40–60% with cardioprotective therapy
    inputs: sbp, lactate, troponin
    advance: Risk stratified with cumulative-dose-weighted recovery candidacy
  8. 8TREATMENT
    Standard CS support (NE first-line per SOAP-II); GDMT 4-pillar — carvedilol + ARNI/ACEi + MRA + SGLT2i — anthracycline-CMP-specific cardioprotection per Cardinale 2015 (PMID 25956652); MCS bridge (IABP/Impella/VA-ECMO) — anthracycline-CMP often shows partial recovery; oncology coordination — discontinue further anthracycline; switch to non-cardiotoxic regimen if active malignancy; transplant evaluation (cancer disease-free interval ≥5 yr historical for solid tumor; modern criteria case-by-case)
    inputs: sbp, lactate
    actions: cardiogenic_shock
    advance: Cardioprotective GDMT initiated + oncology decision + MCS plan documented
  9. 9DISPOSITION
    CICU at MCS-capable + transplant-capable + cardio-onc-capable center; cardio-onc + oncology + advanced HF + transplant MDT activated; advanced HF / transplant evaluation if refractory and cancer disease-status permits
    advance: Disposition assigned with full MDT (cards, advanced HF, oncology, cardio-onc, transplant)
  10. 10MONITORING
    A-line, central line, lactate clearance, urine output; continuous telemetry; serial echo q24h with LVEF + GLS for recovery trajectory; daily troponin + BNP; oncology coordination for cancer status; surveillance for late-effect arrhythmia in dilated chamber
    inputs: lactate, troponin
    actions: panel.cardiac, panel.renal
    advance: Monitoring cadence set + reassessment scheduled with cardio-onc
  11. 11FOLLOWUP
    Repeat echo + GLS at 4–8 wks for recovery trajectory; CMR at 4–8 wks; long-term GDMT 4-pillar maintenance; continued cardio-oncology surveillance (annual echo + GLS); ICD eligibility per AHA 2017 VA/SCD with cancer-prognosis weighting; oncology coordination for ongoing cancer care; dexrazoxane consideration if continued anthracycline therapy required (FDA-approved for metastatic breast cancer ≥300 mg/m² doxorubicin per Swain JCO 1997 PMID 9263800)
    advance: Recovery echo + GLS + GDMT + ICD timeline + cardio-onc surveillance + oncology plan booked